BioNTech SE (22UA) Stock Forecast & Price Target

Compare

54 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

22UA Analyst Ratings

Strong Buy

13 Buy

2 Hold

0 Sell

Based on 15 analysts giving stock ratings to

BioNTech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

22UA Stock 12 Month Forecast

Average Price Target

€120.07

▲(50.28% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is €120.07 with a high forecast of €149.36 and a low forecast of €82.10. The average price target represents a 50.28% change from the last price of €79.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"80":"€80","115":"€115","150":"€150","97.5":"€97.5","132.5":"€132.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":149.35997907,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€149.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":120.0731948699,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€120.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82.10431598,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€82.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[80,97.5,115,132.5,150],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,93.85,98.11999838999999,102.38999677999999,106.65999517,110.92999356,115.19999195,119.46999034000001,123.73998873000001,128.00998712,132.27998551000002,136.5499839,140.81998229,145.08998068,{"y":149.35997907,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,93.85,95.86716883614615,97.8843376722923,99.90150650843846,101.91867534458461,103.93584418073077,105.95301301687692,107.97018185302306,109.98735068916923,112.00451952531537,114.02168836146154,116.03885719760768,118.05602603375384,{"y":120.0731948699,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,93.85,92.94648584461538,92.04297168923077,91.13945753384616,90.23594337846153,89.33242922307691,88.4289150676923,87.52540091230769,86.62188675692308,85.71837260153846,84.81485844615383,83.91134429076922,83.00783013538461,{"y":82.10431598,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":106.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.9,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.85,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€149.36

Average Price Target€120.07

Lowest Price Target€82.10

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emmanuel Papadakis

Deutsche Bank

€122.28

Buy

53.05%

Upside

Reiterated

03/17/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Terence Flynn

Morgan Stanley

€109.18

Buy

36.65%

Upside

Reiterated

03/16/26

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Stevanato Group (NYSE: STVN) and BioNTech SE (NASDAQ: BNTX)

Asthika Goonewardene

Truist Financial

€135.38

Buy

69.44%

Upside

Reiterated

03/13/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), BioNTech SE (NASDAQ: BNTX) and Skye Bioscience (NASDAQ: SKYE)

Yaron Werber

TD Cowen

€101.32→€82.1

Hold

2.76%

Upside

Assigned

03/11/26

Balancing Near-Term Headwinds and Strategic Transition: Why a Hold Rating Remains Warranted

Cory Kasimov

Evercore ISI

€113.55

Buy

42.11%

Upside

Reiterated

03/11/26

Evercore ISI Remains a Buy on BioNTech SE (BNTX)

Geoff Meacham

Citi

€126.65→€113.55

Buy

42.11%

Upside

Reiterated

03/11/26

BioNTech price target lowered to $130 from $145 at CitiBioNTech price target lowered to $130 from $145 at Citi

Mohit Bansal

Wells Fargo

€131.02

Buy

63.98%

Upside

Reiterated

03/11/26

Wells Fargo Sticks to Their Buy Rating for BioNTech SE (BNTX)

Evan Seigerman

BMO Capital

€124.9→€111.8

Buy

39.93%

Upside

Reiterated

03/11/26

BioNTech price target lowered to $128 from $143 at BMO CapitalBioNTech price target lowered to $128 from $143 at BMO Capital

William Maughan

Clear Street

€158.09→€145.87

Buy

82.56%

Upside

Reiterated

03/11/26

Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (NASDAQ: SENS) and BioNTech SE (NASDAQ: BNTX)

Asad Haider

Goldman Sachs

€126.65→€115.3

Buy

44.30%

Upside

Reiterated

03/11/26

BioNTech SE (BNTX) Receives a Buy from Goldman Sachs

John Newman

Canaccord Genuity

€149.36

Buy

86.93%

Upside

Reiterated

03/11/26

Canaccord Genuity Reaffirms Their Buy Rating on BioNTech SE (BNTX)

Akash Tewari

Jefferies

€131.89→€120.54

Buy

50.86%

Upside

Assigned

03/10/26

BioNTech: Attractive Near-Cash Valuation with Robust Late-Stage Pipeline Offsetting Revenue Declines and Leadership Transition Risks

Daina Graybosch

Leerink Partners

€98.7

Hold

23.53%

Upside

Downgraded

02/02/26

BioNTech downgraded to Market Perform from Outperform at LeerinkBioNTech downgraded to Market Perform from Outperform at Leerink

Tazeen Ahmad

Bank of America Securities

€117.04

Buy

46.49%

Upside

Reiterated

01/30/26

Bank of America Securities Remains a Buy on BioNTech SE (BNTX)

Harry Gillis

Berenberg Bank

€135.38

Buy

69.44%

Upside

Reiterated

01/22/26

Berenberg Bank Sticks to Their Buy Rating for BioNTech SE (BNTX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emmanuel Papadakis

Deutsche Bank

€122.28

Buy

53.05%

Upside

Reiterated

03/17/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Terence Flynn

Morgan Stanley

€109.18

Buy

36.65%

Upside

Reiterated

03/16/26

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Stevanato Group (NYSE: STVN) and BioNTech SE (NASDAQ: BNTX)

Asthika Goonewardene

Truist Financial

€135.38

Buy

69.44%

Upside

Reiterated

03/13/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), BioNTech SE (NASDAQ: BNTX) and Skye Bioscience (NASDAQ: SKYE)

Yaron Werber

TD Cowen

€101.32→€82.1

Hold

2.76%

Upside

Assigned

03/11/26

Balancing Near-Term Headwinds and Strategic Transition: Why a Hold Rating Remains Warranted

Cory Kasimov

Evercore ISI

€113.55

Buy

42.11%

Upside

Reiterated

03/11/26

Evercore ISI Remains a Buy on BioNTech SE (BNTX)

Geoff Meacham

Citi

€126.65→€113.55

Buy

42.11%

Upside

Reiterated

03/11/26

BioNTech price target lowered to $130 from $145 at CitiBioNTech price target lowered to $130 from $145 at Citi

Mohit Bansal

Wells Fargo

€131.02

Buy

63.98%

Upside

Reiterated

03/11/26

Wells Fargo Sticks to Their Buy Rating for BioNTech SE (BNTX)

Evan Seigerman

BMO Capital

€124.9→€111.8

Buy

39.93%

Upside

Reiterated

03/11/26

BioNTech price target lowered to $128 from $143 at BMO CapitalBioNTech price target lowered to $128 from $143 at BMO Capital

William Maughan

Clear Street

€158.09→€145.87

Buy

82.56%

Upside

Reiterated

03/11/26

Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (NASDAQ: SENS) and BioNTech SE (NASDAQ: BNTX)

Asad Haider

Goldman Sachs

€126.65→€115.3

Buy

44.30%

Upside

Reiterated

03/11/26

BioNTech SE (BNTX) Receives a Buy from Goldman Sachs

John Newman

Canaccord Genuity

€149.36

Buy

86.93%

Upside

Reiterated

03/11/26

Canaccord Genuity Reaffirms Their Buy Rating on BioNTech SE (BNTX)

Akash Tewari

Jefferies

€131.89→€120.54

Buy

50.86%

Upside

Assigned

03/10/26

BioNTech: Attractive Near-Cash Valuation with Robust Late-Stage Pipeline Offsetting Revenue Declines and Leadership Transition Risks

Daina Graybosch

Leerink Partners

€98.7

Hold

23.53%

Upside

Downgraded

02/02/26

BioNTech downgraded to Market Perform from Outperform at LeerinkBioNTech downgraded to Market Perform from Outperform at Leerink

Tazeen Ahmad

Bank of America Securities

€117.04

Buy

46.49%

Upside

Reiterated

01/30/26

Bank of America Securities Remains a Buy on BioNTech SE (BNTX)

Harry Gillis

Berenberg Bank

€135.38

Buy

69.44%

Upside

Reiterated

01/22/26

Berenberg Bank Sticks to Their Buy Rating for BioNTech SE (BNTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioNTech SE

3 Months

xxx

Success Rate

11/25 ratings generated profit

Average Return

+0.84%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 44.00% of your transactions generating a profit, with an average return of +0.84% per trade.

1 Year

Robert BurnsH.C. Wainwright

Success Rate

12/25 ratings generated profit

Average Return

-0.50%

reiterated a buy rating 3 months ago

Copying Robert Burns's trades and holding each position for 1 Year would result in 48.00% of your transactions generating a profit, with an average return of -0.50% per trade.

2 Years

xxx

Success Rate

10/25 ratings generated profit

Average Return

-6.03%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -6.03% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

22UA Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 22UA has received 24 Buy Ratings, 49 Hold Ratings, and 0 Sell Ratings. 22UA average Analyst price target in the past 3 months is 120.07.

Each month's total comprises the sum of three months' worth of ratings.

22UA Financial Forecast

22UA Earnings Forecast

Next quarter’s earnings estimate for 22UA is -€2.20 with a range of -€3.01 to -€1.33. The previous quarter’s EPS was -€1.25. 22UA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 22UA has Performed in-line its overall industry.

22UA Sales Forecast

Next quarter’s sales forecast for 22UA is €190.43M with a range of €108.89M to €343.70M. The previous quarter’s sales results were €920.41M. 22UA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 22UA has Performed in-line its overall industry.

22UA Stock Forecast FAQ

What is DE:22UA’s average 12-month price target, according to analysts?

Based on analyst ratings, BioNTech SE’s 12-month average price target is 120.07.

What is DE:22UA’s upside potential, based on the analysts’ average price target?

BioNTech SE has 50.28% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BioNTech SE a Buy, Sell or Hold?

BioNTech SE has a consensus rating of Strong Buy, which is based on 13 buy ratings, 2 hold ratings and 0 sell ratings.

What is BioNTech SE’s share price target?

The average share price target for BioNTech SE is 120.07. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €149.36 ,and the lowest forecast is €82.10. The average share price target represents 50.28% Increase from the current price of €79.9.

What do analysts say about BioNTech SE?

BioNTech SE’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of BioNTech SE?

To buy shares of DE:22UA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

BioNTech SE (22UA) Stock Forecast & Price Target

22UA Analyst Ratings

22UA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioNTech SE

22UA Analyst Recommendation Trends

22UA Financial Forecast

22UA Earnings Forecast

22UA Sales Forecast

22UA Stock Forecast FAQ

Detailed List of Analyst Forecasts